Christopher Waddick
Fortune : 172 593 $ au 31/07/2026
Fortune : 172 593 $ au 31/07/2026
Christopher J.
Waddick is Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022, President & Chief Financial Officer at Active Energy, Inc. since 2013, and President at Nrj Consulting, Inc. since 2009.
Formerly, Mr. Waddick was Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Education includes an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/12/2025 | 135 900 ( 0,12 % ) | 172 593 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Directeur Financier/CFO | 16/08/2018 |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Directeur Financier/CFO | 01/01/2013 |
Nrj Consulting, Inc. | President | 01/11/2009 |
| Sociétés | Poste | Fin |
|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 6 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wilfrid Laurier University
Wilfrid Laurier University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Utilities |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Nrj Consulting, Inc. |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national